GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Tempest Therapeutics
Tempest is a biotech company developing cancer treatments. Its stock price is volatile and dependent on clinical trial results. The chart reflects investor confidence in the potential of its scientific platform.
Share prices of companies in the market segment - Cancer cure
Tempest Therapeutics is an oncology company developing drugs aimed at suppressing tumor growth and activating anti-tumor immunity. We've categorized it as a "Cancer Treatment" company. The chart below shows how investors view this high-risk but promising biotech segment.
Broad Market Index - GURU.Markets
Tempest Therapeutics is an oncology company developing drugs aimed at suppressing tumor growth and activating anti-tumor immunity. As a component of the GURU.Markets index, it represents a high-risk but promising segment of biotech. The chart below represents the entire market. See how this company's stock compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
TPST - Daily change in the company's share price Tempest Therapeutics
Tempest Therapeutics' daily share price fluctuations reflect the extreme volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its oncology drugs, serving as a risk assessment tool.
Daily change in the price of a set of shares in a market segment - Cancer cure
Tempest Therapeutics, Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with TPST's dynamics, which depend on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Tempest Therapeutics is a biotech company developing drugs to treat oncology. Its shares are buoyed by anticipation of clinical trial results. These sharp, event-driven movements are part of a complex mosaic of stock market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Tempest Therapeutics
For Tempest Therapeutics, year-over-year performance is a reflection of the development of its oncology drug portfolio. Its 12-month market cap is entirely dependent on clinical trial data. Positive results for its lead candidate, targeting PPARΞ± receptors, could be a breakthrough in liver cancer treatment.
Annual dynamics of market capitalization of the market segment - Cancer cure
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company developing drugs for the treatment of cancer. Its stock performance is entirely dependent on the results of clinical trials. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Tempest Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Tempest Therapeutics
Tempest Therapeutics is a clinical-stage oncology company. Its monthly performance is entirely dependent on the results of its clinical trials. Data on its leading drugs, presented at conferences, are binary events that can cause sharp fluctuations.
Monthly dynamics of market capitalization of the market segment - Cancer cure
Tempest Therapeutics is an oncology company developing drugs that target both tumors and the immune system. The chart below reflects the overall sentiment in the cancer drug development sector, where combination approaches are generating significant interest.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Tempest Therapeutics is a clinical-stage oncology company. Its shares are preoccupied with anticipation of news. Clinical trial results for its drugs could cause a sharp rise or fall, completely ignoring overall market sentiment. It's a high-risk bet on a breakthrough in cancer treatment.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Tempest Therapeutics
Tempest Therapeutics is an oncology biotech. Its weekly stock price is a roller coaster, with every move driven by expectations and clinical trial results. Data releases can cause both a surge and a collapse, as is typical for this sector.
Weekly dynamics of market capitalization of the market segment - Cancer cure
Tempest Therapeutics is an oncology biotech. Its weekly stock price is a roller coaster, with every move driven by expectations and clinical trial results. Data releases can cause both a surge and a collapse, as is typical for this sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Tempest, a biotech company, lives in its own world, far removed from macroeconomic news. Its performance is driven by clinical trial data. A comparison chart with the S&P 500 clearly demonstrates how the stock can rise or fall, completely ignoring the broader market.
Market capitalization of the company, segment and market as a whole
TPST - Market capitalization of the company Tempest Therapeutics
Tempest Therapeutics' market cap is a biotech story focused on developing new cancer treatments. Its stock chart is a classic roller coaster, with sharp rises driven by positive clinical trial data that could attract the attention of major pharmaceutical companies. It's a visual representation of a risky bet on a scientific breakthrough.
TPST - Share of the company's market capitalization Tempest Therapeutics within the market segment - Cancer cure
Tempest Therapeutics is a clinical-stage oncology company whose value is determined by the future of its developments. Its share of the biopharmaceutical segment's market capitalization is an indicator of investor confidence in its scientific platform. The chart below clearly demonstrates how positive research data can dramatically increase a company's value, reflecting its breakthrough potential.
Market capitalization of the market segment - Cancer cure
Tempest Therapeutics is a biopharmaceutical company developing cancer treatments that target the tumor microenvironment. The chart below shows the overall market capitalization of the oncology sector. It illustrates the complexity and diversity of cancer treatment approaches, where Tempest is trying to find its unique niche.
Market capitalization of all companies included in a broad market index - GURU.Markets
This shows a new tactic in immuno-oncology. Tempest Therapeutics is developing drugs that target the tumor microenvironment. Its volatile line on the graph reflects the progress of clinical trials, visualizing the hope that the immune system can be induced to work more effectively.
Book value capitalization of the company, segment and market as a whole
TPST - Book value capitalization of the company Tempest Therapeutics
Tempest Therapeutics' book value is its financial reserves and intellectual property for targeted and immunotherapy cancer drugs. This represents its scientific and financial capital. The chart shows how the biotech company manages its research budget as it develops its innovative approaches to cancer treatment.
TPST - Share of the company's book capitalization Tempest Therapeutics within the market segment - Cancer cure
Tempest Therapeutics develops new cancer drugs, and its main asset is intellectual property. The company's physical assets are its research laboratories. The chart shows the company's minimal share of tangible assets, as its value lies in its promising drug pipeline, not its large manufacturing plants.
Market segment balance sheet capitalization - Cancer cure
Immuno-oncology, as the BCap_Seg chart for biotech shows, is a knowledge-intensive industry. Tempest Therapeutics operates in this environment, where capital is invested in clinical research, not manufacturing. Its assets are intellectual property, not physical infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
Tempest Therapeutics' assets are not factories, but capital fully dedicated to the clinical trials of new oncology drugs. Book value is the financial "fuel reserve" that allows the company to advance its molecules to the stage where they can become real, tangible drugs.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Tempest Therapeutics
Tempest Therapeutics is a clinical-stage oncology company. Its balance sheet doesn't reflect its scientific potential. Its market capitalization is an estimate of the likelihood of its drugs' success. The MvsBCap chart will exhibit extreme volatility, with positive data from a small study potentially driving the valuation, unrelated to its assets, skyrocketing.
Market to book capitalization ratio in a market segment - Cancer cure
Tempest Therapeutics is a biopharmaceutical company developing cancer treatments. Its value is entirely dependent on the success of its clinical programs. This chart shows how investors value the scientific potential of its developments, which is many times greater than its tangible assets.
Market to book capitalization ratio for the market as a whole
Tempest Therapeutics is a biotech company developing cancer treatments. Its market value depends on the results of clinical trials. This chart illustrates how valuations in the pharmaceutical industry can be extremely volatile and based on development news rather than traditional balance sheet metrics.
Debts of the company, segment and market as a whole
TPST - Company debts Tempest Therapeutics
Tempest Therapeutics, a clinical-stage biotech, is using all of its raised capital to fund research into its oncology drugs. Until successful trials and a partnership with major pharma, the company remains unprofitable. This chart shows how the company manages its limited resources in the risky race to develop a new cancer drug.
Market segment debts - Cancer cure
Tempest Therapeutics is a clinical-stage biotech company developing targeted therapies for cancer treatment. Funding long-term, expensive cancer research is its primary focus. This chart provides insight into how Tempest manages its capital to advance its innovative approaches through complex trial phases.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Tempest Therapeutics
Tempest Therapeutics, a biotech company focused on developing cancer drugs, requires significant capital. This chart shows how dependent its survival is on debt to finance clinical trials. High debt is a bet on future success, and failure of a key drug could lead to the company's inability to service it.
Market segment debt to market segment book capitalization - Cancer cure
Tempest Therapeutics is a clinical-stage oncology company developing drugs for the treatment of various types of cancer. This chart shows the level of leverage in the biotech sector. It allows one to assess how the company's financial strategy for raising capital for expensive research compares with the practices of other players in the field.
Debt to book value of all companies in the market
Tempest Therapeutics is a clinical-stage biotechnology company developing drugs to treat various types of cancer. The presented debt-to-equity chart reflects the mood of financial markets. For a company whose future depends on successfully raising funds for expensive clinical trials, this is a critical metric.
P/E of the company, segment and market as a whole
P/E - Tempest Therapeutics
A chart of Tempest Therapeutics, a biopharmaceutical company, shows how investors value its oncology drug portfolio. High values ββreflect not current profits but hopes for success in clinical trials, where any positive result could lead to explosive share price growth.
P/E of the market segment - Cancer cure
This chart shows the average price-to-earnings ratio for the biotech sector in which Tempest Therapeutics is developing. The industry's very high valuation reflects hopes for breakthroughs in cancer treatment. This metric provides a backdrop against which investors evaluate the scientific potential and risks associated with Tempest's oncology portfolio.
P/E of the market as a whole
Tempest Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule drugs that target both tumor and immune cells. This approach combines cancer treatments. This chart illustrates the overall risk appetite in the biotech industry. It provides insight into how investors view Tempest's innovative strategy and how clinical trial data influences its valuation.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Tempest Therapeutics
Tempest Therapeutics is a biopharmaceutical company developing cancer treatments that target novel biological targets. Its valuation is dependent on the success of its clinical programs. This chart reflects analysts' confidence in the company's scientific approach and the potential of its drug candidates to create new cancer treatments.
%20P%2FE%20Tempest%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Tempest-Therapeutics&v=1772586918277 "Chart of the company's future (projected) P/E Tempest Therapeutics")
Future (projected) P/E of the market segment - Cancer cure
Tempest Therapeutics is a biopharmaceutical company developing small-molecule drugs targeting new avenues for cancer treatment. This chart shows how analysts estimate its future revenue compared to other oncology companies. Does the market believe its unique targets will lead to effective treatments?
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-cure&v=1772586918295 "Future (projected) P/E graph of the market segment - Cancer cure")
Future (projected) P/E of the market as a whole
Tempest Therapeutics is a clinical-stage biopharmaceutical company focused on developing new cancer treatments. Its valuation is based on the potential of its pipeline. This chart, reflecting the market's risk appetite, shows how willing investors are to wait for results. During periods of market optimism, funding for such promising but risky companies is more readily available.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772586918339 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Tempest Therapeutics
Tempest Therapeutics is a biotech company developing small-molecule drugs for cancer treatment. Its financial history is one of burning capital on R&D. This chart shows how much the company is investing in its clinical programs, hoping that one of its candidates will become a successful drug and generate future profits.
Profit of companies in the market segment - Cancer cure
Tempest Therapeutics is a biopharmaceutical company developing small-molecule drugs for targeted and immune cancer therapy. Its approach is aimed at activating anti-tumor immunity. This graph illustrates the overall dynamics in oncology, where the search for new mechanisms to fight cancer is attracting huge investments and promises high returns if successful.
Overall market profit
Tempest Therapeutics is a clinical-stage oncology company. Its stock is driven by research news. However, to continue its operations, it needs to raise capital. This chart, reflecting the state of financial markets, affects the conditions under which biotech companies can obtain the necessary financing.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Tempest Therapeutics
Tempest Therapeutics is a biopharmaceutical company developing innovative cancer treatments that target the immune system. This chart shows analysts' estimates of the commercial potential of its pipeline of drug candidates. These forecasts are closely linked to clinical trial progress updates.
%20profit%20of%20the%20company%20Tempest%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Tempest-Therapeutics&v=1772586918427 "Graph of future (projected) profit of the company Tempest Therapeutics")
Future (predicted) profit of companies in the market segment - Cancer cure
Tempest Therapeutics is a clinical-stage biotechnology company developing drugs for the treatment of cancer. Its approach is based on the creation of small-molecule drugs targeting multiple tumor pathways. This chart shows profitability forecasts for the biotech sector. It provides insight into the overall investment climate in oncology, where Tempest is advancing its innovative developments.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-cure&v=1772586918435 "Graph of future (predicted) profits of companies in a market segment - Cancer cure")
Future (predicted) profit of the market as a whole
Tempest Therapeutics is a biotech company developing cancer treatments. Its stock price and funding are dependent on biotech market sentiment and investor risk appetite. This chart, reflecting overall profit expectations, forms a macroeconomic backdrop that influences capital flows into speculative but potentially disruptive industries.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772586918460 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Tempest Therapeutics
Tempest Therapeutics is a biotech company developing cancer drugs. This chart shows an estimate of its future potential. A high market value without significant sales indicates that investors are betting on the success of its clinical trials and the breakthrough nature of its developments.
P/S market segment - Cancer cure
Tempest Therapeutics is a biopharmaceutical company developing small-molecule drugs targeting new cancer treatment pathways. This chart reflects the average revenue estimate in the biotech sector. It provides insight into how investors value the potential future revenue from Tempest's innovative approach to cancer drug development.
P/S of the market as a whole
Tempest Therapeutics is at the forefront of oncology, developing drugs that could transform cancer treatment. The company has no revenue yet, and its value lies in its scientific potential. This chart, reflecting the valuation of companies with actual revenue, serves as a contrast, highlighting the high investor expectations for TPST's future breakthrough.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Tempest Therapeutics
Tempest Therapeutics is a biopharmaceutical company developing small-molecule therapeutics for the treatment of cancer. This chart reflects investor expectations for its clinical programs. The valuation is based on the potential of its candidates to be effective complements to existing immunotherapies, potentially leading to significant future revenue.
%20P%2FS%20Tempest%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Tempest-Therapeutics&v=1772586918507 "The graph of the company's future (projected) P/S Tempest Therapeutics")
Future (projected) P/S of the market segment - Cancer cure
Tempest Therapeutics is a clinical-stage biopharmaceutical company developing combination therapies for various types of cancer. Its goal is to make existing therapies more effective. This chart shows how the market views its innovative approach and pipeline compared to the oncology sector.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20cure&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-cure&v=1772586918629 "Future (projected) P/S market segment graph - Cancer cure")
Future (projected) P/S of the market as a whole
Tempest Therapeutics is a clinical-stage biotech company developing cancer treatments. This chart, reflecting the overall investment climate, is critical to its survival. Investor risk appetite, which rises during periods of optimism, directly impacts Tempest's ability to attract funding to continue its expensive clinical trials.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772586918652 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Tempest Therapeutics
Tempest Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapeutics for the treatment of cancer. This chart reflects revenue, which primarily comes from strategic partnerships with major pharmaceutical companies. It illustrates the financial support that enables the company to advance its innovative oncology programs through clinical trials.
Sales of companies in the market segment - Cancer cure
Tempest Therapeutics is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies that target both tumors and the immune system. Its operations are segmented into various development programs. This chart depicts the financial flows associated with one of its key drug candidates.
Overall market sales
Tempest Therapeutics is a biotech company developing new cancer treatments. Its market capitalization is determined by expectations from clinical trials. The success or failure of its drugs can dramatically alter the company's prospects, regardless of the overall economic situation. It is an example of a business driven by science, not macroeconomic cycles.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Tempest Therapeutics
Tempest Therapeutics is a clinical-stage biopharmaceutical company developing combination therapies for various types of cancer. Its future sales forecast is based on expectations for the success of its clinical trials, particularly for its lead drug, which has shown promising results in the treatment of liver cancer.
%20sales%20of%20the%20company%20Tempest%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Tempest-Therapeutics&v=1772586918766 "Schedule of future (projected) sales of the company Tempest Therapeutics")
Future (projected) sales of companies in the market segment - Cancer cure
Tempest Therapeutics is a clinical-stage biotechnology company developing targeted therapies for cancer treatment. This chart reflects expectations for the entire oncology sector. It allows analysts to assess the commercial potential of new treatment approaches targeting specific tumor biomarkers.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-cure&v=1772586918835 "Schedule of future (projected) sales of companies in the market segment - Cancer cure")
Future (projected) sales of the market as a whole
Tempest Therapeutics, a biotech company developing cancer treatments, is a company whose value and ability to raise funding depend on the success of clinical trials and overall market sentiment. This sales forecast chart reflects economic confidence, which influences investors' risk appetite.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772586918867 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Tempest Therapeutics
Tempest Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule drugs for the treatment of various types of cancer. This chart reflects the financial reality of innovative biotech: significant R&D expenditures lay the foundation for a future where successful trials can lead to high profitability.
Market segment marginality - Cancer cure
Tempest Therapeutics is a biopharmaceutical company developing small-molecule drugs for cancer treatment. The key to success in this type of business is the ability of their R&D engine to generate promising candidates and advance them through clinical trials at an optimal cost. The chart below shows their operating model.
Market marginality as a whole
Tempest Therapeutics is a biotech company developing small-molecule drugs for the treatment of cancer. Its strategy is focused on creating combinations with existing treatments. This chart shows the profitability of mature businesses, while for TPST, success depends on the results of clinical trials and the ability of its drugs to significantly improve patient outcomes.
Employees in the company, segment and market as a whole
Number of employees in the company Tempest Therapeutics
Tempest Therapeutics is a clinical-stage oncology company developing novel cancer treatments. This chart shows the size of its team of scientists and clinical trial specialists. This team's growth is directly related to advancing its drug candidates through complex and costly clinical trials.
Share of the company's employees Tempest Therapeutics within the market segment - Cancer cure
Tempest Therapeutics is a biotech company developing targeted drugs for cancer treatment. Its approach requires deep scientific expertise and a large team to conduct clinical trials. This chart shows its staff contributions to the overall effort to find new and more effective ways to fight cancer.
Number of employees in the market segment - Cancer cure
Tempest Therapeutics is a clinical-stage biopharmaceutical company developing combination therapies for the treatment of cancer. This chart reflects employment in the oncology sector. The growing number of clinicians and scientists in this field indicates a shift toward complex, multicomponent approaches to cancer treatment, which aligns with Tempest's scientific strategy.
Number of employees in the market as a whole
Tempest Therapeutics is an oncology company, and its growth depends on clinical success. This graph reflects overall workload, but for Tempest, publishing positive trial results could be a catalyst for attracting investment and hiring dozens of new scientists, regardless of the economic climate.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Tempest Therapeutics (TPST)
Tempest Therapeutics, Inc. is a biopharmaceutical company developing cancer treatments. The high value on this chart reflects the fact that the company's entire value is concentrated in its scientific potential. The market is betting on the future success of clinical trials conducted by a relatively small team of specialists.
%20of%20the%20company%20Tempest%20Therapeutics%20(TPST)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Tempest-Therapeutics-TPST&v=1772586919094 "Chart of market capitalization per employee (in thousands of dollars) of the company Tempest Therapeutics (TPST)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer cure
Tempest Therapeutics is a clinical-stage biopharmaceutical company developing targeted therapies for cancer. Its market value per employee is a direct reflection of investors' assessment of the company's scientific potential and development prospects. This chart compares how highly the market values ββits team and drug portfolio relative to other oncology players.
%20by%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-cure&v=1772586919109 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer cure")
Market capitalization per employee (in thousands of dollars) for the overall market
Tempest Therapeutics is a biotech company developing small-molecule drugs for cancer treatment. Its future depends on the success of its clinical programs. This chart illustrates the high, albeit risky, value the market places on the intellectual capital and scientific research of a small team of oncologists.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772586919130 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Tempest Therapeutics (TPST)
Tempest Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule drugs for the treatment of cancer. Currently, the company has no revenue from its products. This chart is an indicator of R&D intensity. It reflects how much capital is invested in each scientist and clinical trial staff member to advance their drug candidates through the complex approval process.
%20Chart%20Tempest%20Therapeutics%20(TPST)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Tempest-Therapeutics-TPST&v=1772586919135 "Company Profit Per Employee (in thousands of dollars) Chart Tempest Therapeutics (TPST)")
Profit per employee (in thousands of dollars) in the market segment - Cancer cure
Tempest Therapeutics is a biopharmaceutical company developing small-molecule drugs for cancer treatment. In this industry, a small team of scientists can create a product with billion-dollar potential. This metric reflects how effectively the team converts scientific research into value and serves as a benchmark for comparison with other oncology startups.
%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-cure&v=1772586919150 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer cure")
Profit per employee (in thousands of dollars) for the market as a whole
Tempest Therapeutics is a clinical-stage biotech focused on oncology. Like other R&D companies, it has no product revenue. This metric is negative and reflects not efficiency but rather the "burn rate" of capital per employee. It tells investors how much it costs to maintain a scientific team working on developing future drugs.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772586919197 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Tempest Therapeutics (TPST)
Tempest Therapeutics is a clinical-stage oncology company. Its revenue per employee, if any, likely comes from partnerships rather than sales. This chart shows a bet on the future success of its clinical programs, which could lead to a sharp increase in this figure.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Tempest-Therapeutics-TPST&v=1772586919204 "Sales chart per company employee Tempest Therapeutics (TPST)")
Sales per employee in the market segment - Cancer cure
Tempest Therapeutics is an oncology company developing small-molecule drugs that target both tumors and the immune system. This chart compares revenue per employee (R&D) to the industry average. For a research-stage company, this reflects the value of their partnerships and the effectiveness of their scientific platform.
Sales per employee for the market as a whole
Tempest Therapeutics is a clinical-stage biotech developing novel cancer treatments. They focus on drugs that target tumors and the immune system. Like other companies at this stage (ACLX, ESTA), they have no commercial revenue. This chart will show $0 or partnership revenue, as the company focuses on R&D.
Short shares by company, segment and market as a whole
Shares shorted by company Tempest Therapeutics (TPST)
Tempest Therapeutics (TPST) is an oncology company whose shares experienced incredible volatility after the release of data on one of its drugs. In biotech, positive data often follows a decline in subsequent stages. This chart shows the number of investors who believe the initial optimism was overdone and the drug will ultimately fail.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Tempest-Therapeutics-TPST&v=1772586919278 "Short Shares Chart for the Company Tempest Therapeutics (TPST)")
Shares shorted by market segment - Cancer cure
Tempest Therapeutics is an oncology company developing small-molecule drugs that target the immune system to fight tumors. This chart shows the odds against the oncology biotech sector. It reflects the general pessimism of investors, who are betting that most drugs in this crowded sector will not prove effective.
Shares shorted by the overall market
Tempest (TPST) is a clinical-stage biotech. Its value is based on future expectations. When this market fear indicator rises, investors' risk appetite evaporates. They are the first to sell speculative, loss-making biotechs like TPST in favor of safer assets.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Tempest Therapeutics (TPST)
Tempest Therapeutics is an oncology company developing targeted therapies. The company's shares can exhibit extreme volatility, such as after the release of positive data on one of its drugs. This oscillator clearly identifies such moments of "overheating" (above 70), when investor euphoria reaches its peak.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Tempest-Therapeutics-TPST&v=1772586919333 "RSI 14 indicator chart for the company's stock Tempest Therapeutics (TPST)")
RSI 14 Market Segment - Cancer cure
Tempest Therapeutics is a biotech company developing cancer treatments that target multiple immune system pathways. This chart measures the collective excitement in the oncology biotech sector. It helps determine whether the entire segment is overheated by speculative expectations of clinical success.
RSI 14 for the overall market
For Tempest Therapeutics, a biotech in R&D, this chart is a lifeline showing capital availability. During periods of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the cash spigot is turned off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast TPST (Tempest Therapeutics)
Tempest Therapeutics is a biotech company developing targeted therapies for cancer treatment. This chart shows the average Wall Street price target. Analysts' forecasts are based on clinical data, the potential of their lead candidates (e.g., in combinations), and the overall market size for their oncology pipeline.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-TPST-Tempest-Therapeutics&v=1772586919399 "A chart showing analyst consensus forecasts for the expected stock price. TPST (Tempest Therapeutics)")
The difference between the consensus estimate and the actual stock price TPST (Tempest Therapeutics)
Tempest Therapeutics is a biotech company focused on developing a new class of oncology drugs (including TPST-1120 for liver cancer). This chart shows the growth potential analysts see. It measures the distance between the current share price and the consensus target price, which for an R&D company is a direct estimate of the chances of clinical success.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-TPST-Tempest-Therapeutics&v=1772586919424 "A chart showing the difference between the consensus forecast and the actual stock price. TPST (Tempest Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Cancer cure
Tempest Therapeutics is a clinical-stage biotech company developing cancer treatments that target the tumor microenvironment. This chart shows the overall analyst expectations for the oncology sector. It reflects the experts' confidence in the success of this high-risk R&D platform.
Analysts' consensus forecast for the overall market share price
Tempest Therapeutics is a biotech company developing cancer treatments that target cancer stem cells. This chart reflects the overall risk appetite in the market. For Tempest, which has yet to generate revenue, the overall analyst optimism (the rising chart) is critical to raising the capital needed to fund expensive research.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Tempest Therapeutics
Tempest is a clinical-stage biotech focused on developing next-generation cancer treatments (including immuno-oncology). It's an R&D business with binary risk. This chart is purely an indicator of faith in their science. It doesn't reflect current sales, but rather a speculative assessment of their R&D progress, clinical trial data, and chances of approval.
AKIMA Market Segment Index - Cancer cure
Tempest Therapeutics (TPST) is a clinical-stage biotech company attacking cancer from new angles, with programs aimed at activating the immune system and inhibiting tumor growth pathways. This chart shows the average index value for the segment. It allows investors to compare TPST's risk-reward profile with the collective benchmark of its competitors in the oncology space.
The AKIM Index for the overall market
Tempest Therapeutics is an oncology company developing small molecules to target the tumor microenvironment. Its primary asset is TPST-1120 (for liver cancer). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this promising clinical case compares to overall economic trends.
